{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:35Z","timestamp":1740120095722,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s12185-021-03259-8","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T13:04:31Z","timestamp":1637154271000},"page":"329-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"115","author":[{"given":"Mika","family":"Nakamae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-990X","authenticated-orcid":false,"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asao","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"3259_CR1","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440\u201353.","journal-title":"Leukemia"},{"key":"3259_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood"},{"key":"3259_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, IRIS Investigators, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"3259_CR4","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"3259_CR5","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","volume":"103","author":"C Gambacorti-Passerini","year":"2018","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study. Haematologica. 2018;103:1298\u2013307.","journal-title":"Haematologica"},{"key":"3259_CR6","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","volume":"7","author":"S Kimura","year":"2020","unstructured":"Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7:e218\u201325.","journal-title":"Lancet Haematol"},{"key":"3259_CR7","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375\u201383.","journal-title":"Lancet Haematol"},{"key":"3259_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, EURO-SKI Investigators, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"3259_CR9","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","volume":"103","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, STAT Study Group, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103:1835\u201342.","journal-title":"Haematologica"},{"key":"3259_CR10","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, G\u00f3mez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525\u201331.","journal-title":"Leukemia"},{"key":"3259_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298\u2013305.","journal-title":"J Clin Oncol"},{"key":"3259_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"NP Shah","year":"2020","unstructured":"Shah NP, Garc\u00eda-Guti\u00e9rrez V, Jim\u00e9nez-Velasco A, Larson S, Saussele S, Rea D, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61:650\u20139.","journal-title":"Leuk Lymphoma"},{"key":"3259_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2019.10.036","volume":"301","author":"G Caocci","year":"2020","unstructured":"Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, Bonifacio M, et al. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. Int J Cardiol. 2020;301:163\u20136.","journal-title":"Int J Cardiol"},{"key":"3259_CR14","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00277-019-03705-y","volume":"98","author":"G Caocci","year":"2019","unstructured":"Caocci G, Mulas O, Abruzzese E, Iurlo A, Annunziata M, Orlandi EM, et al. Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. Ann Hematol. 2019;98:1885\u201390.","journal-title":"Ann Hematol"},{"key":"3259_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","volume":"48","author":"DJ Dorer","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84\u201391.","journal-title":"Leuk Res"},{"key":"3259_CR16","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210\u20138.","journal-title":"J Clin Oncol"},{"key":"3259_CR17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/leu.2014.342","volume":"29","author":"D Rea","year":"2015","unstructured":"Rea D, Mirault T, Raffoux E, Boissel N, Andreoli AL, Rousselot P, et al. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia. 2015;29:1206\u20139.","journal-title":"Leukemia"},{"key":"3259_CR18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/njcp.njcp_33_18","volume":"22","author":"L Li","year":"2019","unstructured":"Li L, Liu W, Zeng Z, Chen S. Acute ischemic intestinal necrosis as a rare side effect of nilotinib. Niger J Clin Pract. 2019;22:131\u20133.","journal-title":"Niger J Clin Pract"},{"key":"3259_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.12809\/hkmj176972","volume":"25","author":"YL Boo","year":"2019","unstructured":"Boo YL, Liam CCK, Lim SY, Look ML. Cardiovascular event in chronic myeloid leukaemia treated with tyrosine kinase inhibitor: a case report. Hong Kong Med J. 2019;25:74\u20135.","journal-title":"Hong Kong Med J"},{"key":"3259_CR20","first-page":"11","volume":"4","author":"T Miyoshi","year":"2016","unstructured":"Miyoshi T, Ito H. Assessment of arterial stiffness using the cardio-ankle vascular index. Pulse (Basel). 2016;4:11\u201323.","journal-title":"Pulse (Basel)"},{"key":"3259_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5551\/jat.13.101","volume":"13","author":"K Shirai","year":"2006","unstructured":"Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006;13:101\u20137.","journal-title":"J Atheroscler Thromb"},{"key":"3259_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1253\/circj.71.89","volume":"71","author":"T Kubozono","year":"2007","unstructured":"Kubozono T, Miyata M, Ueyama K, Nagaki A, Otsuji Y, Kusano K, et al. Clinical significance and reproducibility of new arterial distensibility index. Circ J. 2007;71:89\u201394.","journal-title":"Circ J"},{"key":"3259_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1291\/hypres.27.625","volume":"27","author":"M Yambe","year":"2004","unstructured":"Yambe M, Tomiyama H, Hirayama Y, Gulniza Z, Takata Y, Koji Y, et al. Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure. Hypertens Res. 2004;27:625\u201331.","journal-title":"Hypertens Res"},{"key":"3259_CR24","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","volume":"12","author":"S Cirmi","year":"2020","unstructured":"Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers (Basel). 2020;12:826.","journal-title":"Cancers (Basel)"},{"key":"3259_CR25","first-page":"649","volume":"208","author":"JF Polak","year":"1998","unstructured":"Polak JF, Shemanski L, O\u2019Leary DH, Lefkowitz D, Price TR, Savage PJ, et al. Hypoechoic plaque at US of the carotid artery: an independent risk factor for incident stroke in adults aged 65 years or older. Cardiovasc Health Study Radiol. 1998;208:649\u201354.","journal-title":"Cardiovasc Health Study Radiol"},{"key":"3259_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"3259_CR27","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1253\/circj.CJ-08-0152","volume":"72","author":"M Izuhara","year":"2008","unstructured":"Izuhara M, Shioji K, Kadota S, Baba O, Takeuchi Y, Uegaito T, et al. Relationship of cardio-ankle vascular index (CAVI) to carotid and coronary arteriosclerosis. Circ J. 2008;72:1762\u20137.","journal-title":"Circ J"},{"key":"3259_CR28","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316\u201321.","journal-title":"Leukemia"},{"key":"3259_CR29","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1055\/s-0038-1624566","volume":"2","author":"H Haguet","year":"2018","unstructured":"Haguet H, Douxfils J, Chatelain C, Graux C, Mullier F, Dogn\u00e9 JM. BCR-ABL tyrosine kinase inhibitors: which mechanism(s) may explain the risk of thrombosis? TH Open. 2018;2:e68\u201388.","journal-title":"TH Open"},{"key":"3259_CR30","doi-asserted-by":"publisher","first-page":"e12625","DOI":"10.1111\/micc.12625","volume":"27","author":"MJ Durand","year":"2020","unstructured":"Durand MJ, Hader SN, Derayunan A, Zinkevich N, McIntosh JJ, Beyer AM. BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature. Microcirculation. 2020;27:e12625.","journal-title":"Microcirculation"},{"key":"3259_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","volume":"60","author":"A Gover-Proaktor","year":"2019","unstructured":"Gover-Proaktor A, Granot G, Pasmanik-Chor M, Pasvolsky O, Shapira S, Raz O, et al. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk Lymphoma. 2019;60:189\u201399.","journal-title":"Leuk Lymphoma"},{"key":"3259_CR32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3389\/fphar.2020.01007","volume":"11","author":"H Haguet","year":"2020","unstructured":"Haguet H, Bouvy C, Delvigne AS, Modaffari E, Wannez A, Sonveaux P, et al. The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: an in-vitro study. Front Pharmacol. 2020;11:1007.","journal-title":"Front Pharmacol"},{"key":"3259_CR33","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","volume":"133","author":"Y Latifi","year":"2019","unstructured":"Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, L\u00f3pez JA, Lindner JR. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood. 2019;133:1597\u2013606.","journal-title":"Blood"},{"key":"3259_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/cam4.2687","volume":"9","author":"S Deb","year":"2020","unstructured":"Deb S, Bokn\u00e4s N, Sj\u00f6str\u00f6m C, Tharmakulanathan A, Lotfi K, Ramstr\u00f6m S. Varying effects of tyrosine kinase inhibitors on platelet function\u2014a need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications? Cancer Med. 2020;9:313\u201323.","journal-title":"Cancer Med"},{"key":"3259_CR35","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1080\/09537104.2018.1501470","volume":"30","author":"G Mezei","year":"2019","unstructured":"Mezei G, Debreceni IB, Kerenyi A, Remenyi G, Szasz R, Illes A, et al. Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia. Platelets. 2019;30:836\u201343.","journal-title":"Platelets"},{"key":"3259_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12872-021-02095-2","volume":"21","author":"MH Yazdanpanah","year":"2021","unstructured":"Yazdanpanah MH, Bahramali E, Naghizadeh MM, Farjam M, Mobasheri M, Dadvand S. Different body parts\u2019 fat mass and corrected QT interval on the electrocardiogram: the Fasa PERSIAN Cohort Study. BMC Cardiovasc Disord. 2021;21:277.","journal-title":"BMC Cardiovasc Disord"},{"key":"3259_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/pace.13292","volume":"41","author":"N Zhang","year":"2018","unstructured":"Zhang N, Gong M, Tse G, Zhang Z, Meng L, Yan BP, et al. Prolonged corrected QT interval in predicting atrial fibrillation: a systematic review and meta-analysis. Pacing Clin Electrophysiol. 2018;41:321\u20137.","journal-title":"Pacing Clin Electrophysiol"},{"key":"3259_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","volume":"6","author":"JE Tisdale","year":"2013","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479\u201387.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3259_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12028-013-9873-7","volume":"19","author":"N Henninger","year":"2013","unstructured":"Henninger N, Haussen DC, Kakouros N, Selim M, Searls DE, Kumar S, et al. QTc-prolongation in posterior circulation stroke. Neurocrit Care. 2013;19:167\u201375.","journal-title":"Neurocrit Care"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03259-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T19:44:13Z","timestamp":1699818253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03259-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3259"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03259-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"17 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MN received honoraria from Novartis and payment (honoraria) to spouse (Please refer to H. Nakamae disclosure). HN received honoraria from Pfizer Japan Inc. and Takeda Pharmaceutical Co., Ltd., and research funding and honoraria from Novartis, Bristol Myers Squibb, and Otsuka Pharmaceutical. HK received honoraria from Novartis, and honoraria and research funding from Takeda Pharmaceutical Co., Ltd. YN received honoraria from Pfizer Japan Inc., and honoraria and research funding from Novartis. MHino received honoraria from Pfizer Japan Inc., Bristol Myers Squibb, Novartis, Takeda Pharmaceutical Co., Ltd, and Otsuka Pharmaceutical, research funding from Pfizer Japan Inc. Takeda Pharmaceutical Co., Ltd and Novartis, and donations made to the university that were not limited to specific research purposes from Pfizer Japan Inc. and Otsuka Pharmaceutical. MHa and AH have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}